Mizuho Markets Americas’s Sarepta Therapeutics SRPT Stock Holding History

Mizuho Markets Americas’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-227,264	Closed	-$14.5M	–	220
2025 Q1	$14.5M	Sell	227,264 -178,451	-44%	-$18.8M	0.3%	64
2024 Q4	$49.3M	Buy	405,715 +6,650	+2%	+$815K	0.88%	32
2024 Q3	$49.8M	Buy	399,065 +72,765	+22%	+$10.1M	1.03%	22
2024 Q2	$51.6M	Buy	326,300 +35,500	+12%	+$4.56M	1.24%	17
2024 Q1	$37.6M	Sell	290,800 -14,839	-5%	-$1.82M	0.93%	21
2023 Q4	$29.5M	Buy	305,639 +59,700	+24%	+$5.73M	0.83%	21
2023 Q3	$29.8M	Buy	+245,939	New	+$27.8M	1.04%	16
2023 Q2	–	Sell	-259,809	Closed	-$35.8M	–	76
2023 Q1	$35.8M	Buy	259,809 +67,379	+35%	+$8.74M	1.44%	17
2022 Q4	$24.9M	Buy	+192,430	New	+$22.3M	1.47%	15

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Mizuho Markets Americas's SRPT Position: Q2 2025 in Review

Mizuho Markets Americas sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 227,264 shares — an estimated $14.5M sold.

Mizuho Markets Americas first reported a position in SRPT in Q4 2022 and held it in 9 quarters. The position peaked at $51.6M in Q2 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

Mizuho Markets Americas reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
Mizuho Markets Americas sold 227,264 Sarepta Therapeutics shares in Q2 2025, an estimated $14.5M.
Mizuho Markets Americas first reported a position in Sarepta Therapeutics in Q4 2022 and held it in 9 quarters.
Mizuho Markets Americas's Sarepta Therapeutics position peaked at $51.6M in Q2 2024.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Mizuho Markets Americas's 13F filing for Q2 2025, filed 1 Aug 2025.